At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Veriset Hemostatic Patch +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-Center, Randomized, Single-Blind Study to Compare the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery
In Brief
A clinical study evaluating Veriset Hemostatic Patch and Fibrin Sealant (TachoSil®) for Liver Disease. Completed, enrolled 50 participants across 6 sites in 3 countries.
Detailed Summary
The objective of this study is to evaluate the safety and effectiveness of Covidien's Hemostatic Patch to control bleeding during hepatic surgery. The performance of the Hemostatic Patch will be compared to Control as an adjunct to conventional hemostatic techniques.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Disease
CountriesAustria, Belgium, Germany
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedMar 2011
Primary CompletionSep 2011
TodayJul 2026
First PostedMar 29, 2011
Enrollment StartFeb 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.3 years ago
Interventions
Veriset Hemostatic Patchdevice
Topical hemostat
Fibrin Sealant (TachoSil®)device
Topical hemostat